HUMANIZED MOUSE MODELS
Versatility and reproducibility in oncology studies.
Humanized mouse models are the swiss-knives of preclinical models: they can be used to identify tumor stem cells, investigate tumor cell biology, identify and test potential drugs, and get a better insight on metastasis. Finding a CRO that provides you with the study designs and models you need for your immunological trials can be as daunting as the trials themselves: Hu-PBL-scid models ensuring flawless memory T cells, or Hu-SRC-scid models which will guarantee the multilineage development of hematopoietic stem cells, is challenging at best.
As the need for humanized models grows exponentially with all advances made in immunology, the lack of reliable, cost-effective platforms is proving to be an obstacle that many are finding hard to overcome. But not at Pharmalegacy.
Models / Services
The development of CD34+ humanized mouse model:
We reconstitute NOG/NPG immunocompromised mice with a human hematopoietic system via engraftment of human cord blood CD34+ cells. The level of humanization is determined by human CD45+ cell ratio, which ranges from 40% to 60% with the majority of T and B cells in the peripheral blood 16 weeks after engraftment. Any mouse with >15% hCD45+ cells is considered as a valid model according to various dosing studies. The CD34+ humanized mice have the longest research span (over a year) without graft-versus-host disease.
Level of “humanization” (human CD45+ cells ratio) ranged between 40%-60%, with little variation between batches of hCD34+ HSC transplanted animals.
Level of human T cells reconstitution in peripheral blood increased continuously post hCD34+ HSC transplantation.
Availability of human tumor cell lines
| Tumor Type | Cell Lines Validated | Tumor Type | Cell Lines Under Validation |
| Melanoma |
A375 SK-MEL-5 |
NSCLC |
EBC-1 NCI-H226 |
| Epidermoid Carcinoma | A431 | Melanoma |
SK-MEL-28 A2058 |
| Lung Cancer Cell | NCI-H1975
HCC-827 A549 |
Glioma | U251MG |
| Breast Cancer |
HCC1954 MDA-MB-231 JIMT-1 |
||
| Colon Cancer | HT29 | ||
| Gastric Cancer | MKN45
NCI-N87 |
||
| Lymphoma | Raji | ||
| Myeloma | RPMI8226 | ||
| Glioma | U87MG | ||
Case Study: Immune Checkpoint Inhibitors-Evaluating mAb PD-1/PD-L1 in HCC-827 Model
Case Study: Immune Checkpoint Inhibitors-Evaluating mAb PD-1 in U87MG Model
Case Study: Combination Therapy-Evaluating mAbs PD-1 and EGFR in HCC-827 Model
Case Study: Bi-Specific Ab
Evaluating Bi-Specific Ab in NC1-N87 Model
Evaluating Bi-Specific Ab in HCC827 Model
Case Study: Oncolytic Virus
Evaluating Oncolytic Virus in HCC827 Model
The Development of CD34+ Humanized Mouse Model
Human T Cell Proliferation in PB of HCC827 hCD34+ Humanized Model
PD-1/PD-L1 Combination Therapy in HCC827 hCD34+ Humanized Model
PD-L1&VEGF Combination Therapy in U87MG hCD34+ Humanized Model
PD-1&HER-2 Combination Therapy in HCC1954 hCD34+ Humanized Model
PD-1/PD-L1-VEGF Bi-Specific Abs Therapy in hCD34+ Humanized Model
Oncolytic Virotherapy in hCD34+ Humanized Model
Cell Lines Validated in hCD34+ Humanized Model
Production of 2nd Humanized Mice at Pharmalegacy
NO WAITING cohorts from Mix-donor HSCs
Reconstitution of Human Immune Systems in 2nd Humanized Mice
HCC827 in Different Batches of 2nd Humanized Mice
Efficacy Study in A549 2nd Humanized Mice Model
Two different PBMC delivery approach:
1. Pre-mix PBMC and tumor cells then inject them subcutaneously;
2. Before tumor cell inoculation, injection of PBMC intravenously or intraperitoneally.
Readouts:
Body weight, tumor growth inhibition, annotation of tumor infiltrating leukocytes (TIL) and tumor cells.
Committed to quality:
- Capacity to house over 30,000 rodents and large animals
- Scientific staff with an average of over 15 years of pharmacology experience.
- FDA Part 11 compliant
- 24/7 access to PharmaLegacy representatives.
Never settle for less in your preclinical oncology trial. Contact us at PharmaLegacy let’s talk about your expectations, and how we can exceed them together.
Top Pharmaceutical Companies Trust PharmaLegacy for their Oncology Trials
“The study they delivered on a very reasonable budget was top notch […] The model was executed flawlessly.”
See why a top-20 pharmaceutical company trusts PharmaLegacy for their preclinical immuno-oncology trials.
We’re ready when you are.
Tell us your pharmacology challenges.
